| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 04/06/2024 | 23:13 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 03/06/2024 | 17:00 | GlobeNewswire Inc. | Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 16/05/2024 | 03:31 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 13/05/2024 | 22:47 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 09/05/2024 | 22:34 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 09/05/2024 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics to Participate at Upcoming Investor Events | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 08/05/2024 | 13:00 | GlobeNewswire Inc. | Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 01/05/2024 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024 | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 29/04/2024 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024 | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 15/04/2024 | 23:01 | GlobeNewswire Inc. | Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 10/04/2024 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 28/03/2024 | 21:32 | GlobeNewswire Inc. | Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 28/03/2024 | 12:42 | IH Market News | US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 26/03/2024 | 21:30 | GlobeNewswire Inc. | Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 25/03/2024 | 21:30 | GlobeNewswire Inc. | Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 18/03/2024 | 12:30 | GlobeNewswire Inc. | Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024 | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 04/03/2024 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 28/02/2024 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics to Participate at Upcoming Investor Conferences | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 14/02/2024 | 22:51 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 06/02/2024 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 02/02/2024 | 13:13 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 23/01/2024 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 11/01/2024 | 22:50 | Dow Jones News | Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 08/01/2024 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 04/01/2024 | 14:55 | GlobeNewswire Inc. | Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 27/12/2023 | 14:24 | Dow Jones News | Zevra Therapeutics Refiles Arimoclomol Application With FDA | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 27/12/2023 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 20/11/2023 | 13:30 | GlobeNewswire Inc. | Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 07/11/2023 | 13:00 | GlobeNewswire Inc. | Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results | NASDAQ:ZVRA | Zevra Therapeutics Inc |
| 31/10/2023 | 12:30 | GlobeNewswire Inc. | Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET | NASDAQ:ZVRA | Zevra Therapeutics Inc |